ATE46170T1 - Verwendung von an ein interkalatines produkt gebundenen oligonukleotiden fuer pharmazeutische zusammensetzungen. - Google Patents

Verwendung von an ein interkalatines produkt gebundenen oligonukleotiden fuer pharmazeutische zusammensetzungen.

Info

Publication number: ATE46170T1
Authority: AT; Austria
Prior art keywords: nucleic acid; acid sequence; oligonucleotide; intercalatine; product
Prior art date: 1984-07-25

Application number

AT85401506T

Other languages

English (en)

Inventor

Claude Helene

Thanh Thuong Nguyen

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-07-25

Filing date

1985-07-22

Publication date

1989-09-15

1985-07-22 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

1989-09-15 Application granted granted Critical

1989-09-15 Publication of ATE46170T1 publication Critical patent/ATE46170T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000007523 nucleic acids Chemical group 0.000 abstract 6
108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
230000000295 complement effect Effects 0.000 abstract 2
150000001875 compounds Chemical group 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
230000000977 initiatory effect Effects 0.000 abstract 2
239000000138 intercalating agent Substances 0.000 abstract 2
238000009830 intercalation Methods 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
102000039446 nucleic acids Human genes 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
230000010076 replication Effects 0.000 abstract 2
238000013518 transcription Methods 0.000 abstract 2
230000035897 transcription Effects 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT85401506T 1984-07-25 1985-07-22 Verwendung von an ein interkalatines produkt gebundenen oligonukleotiden fuer pharmazeutische zusammensetzungen. ATE46170T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8411795A FR2568254B1 (fr)	1984-07-25	1984-07-25	Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament
EP85401506A EP0169787B1 (de)	1984-07-25	1985-07-22	Verwendung von an ein interkalatines Produkt gebundenen Oligonukleotiden für pharmazeutische Zusammensetzungen

Publications (1)

Publication Number	Publication Date
ATE46170T1 true ATE46170T1 (de)	1989-09-15

Family

ID=9306479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT85401506T ATE46170T1 (de)	1984-07-25	1985-07-22	Verwendung von an ein interkalatines produkt gebundenen oligonukleotiden fuer pharmazeutische zusammensetzungen.

Country Status (6)

Country	Link
EP (1)	EP0169787B1 (de)
JP (1)	JP2521426B2 (de)
AT (1)	ATE46170T1 (de)
CA (1)	CA1321363C (de)
DE (1)	DE3572825D1 (de)
FR (1)	FR2568254B1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1223831A (en)	1982-06-23	1987-07-07	Dean Engelhardt	Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US7220854B1 (en)	1982-06-23	2007-05-22	Enzo Life Sciences, Inc. C/O Enzo Biochem, Inc.	Sugar moiety labeled nucleotide, and an oligo- or polynucleotide, and other compositions comprising such sugar moiety labeled nucleotides
US4734363A (en) *	1984-11-27	1988-03-29	Molecular Diagnostics, Inc.	Large scale production of DNA probes
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5637573A (en) *	1986-05-23	1997-06-10	Agrawal; Sudhir	Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5912339A (en) *	1986-10-28	1999-06-15	The Johns Hopkins University	Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
EP0266099A3 (de) *	1986-10-28	1990-09-19	The Johns Hopkins University	Alkyl- oder Arylphosphonat-Oligonukleosid, das sich mit Nukleinesäuren vernetzen kann oder das Nukleinsäure spalten kann
FR2612930B1 (fr) *	1987-03-27	1990-12-28	Centre Nat Rech Scient	Sondes oligonucleotidiques a
EP0290583B1 (de) *	1986-12-02	1993-04-07	Centre National De La Recherche Scientifique (Cnrs)	Alpha-oligonukleotide
FR2607507B1 (fr) *	1986-12-02	1990-04-13	Centre Nat Rech Scient	Nouveaux derives a-d-oligonucleotides, leur preparation et leur emploi
US5789155A (en)	1987-10-30	1998-08-04	California Institute Of Technology	Process for identifying nucleic acids and triple helices formed thereby
US5874555A (en) *	1987-10-30	1999-02-23	California Institute Of Technology	Triple helices and processes for making same
IT1211498B (it) *	1987-11-05	1989-11-03	Cselt Centro Studi Lab Telecom	Procedimento per ridurre l attenuazione in fibre ottiche
DE3738460A1 (de) *	1987-11-12	1989-05-24	Max Planck Gesellschaft	Modifizierte oligonukleotide
GB8728468D0 (en) *	1987-12-04	1988-01-13	Sonceboz Sa	Fluidic flowmeter
JPH03503894A (ja) *	1988-03-25	1991-08-29	ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション	オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
DE3916871A1 (de) *	1989-05-24	1990-11-29	Boehringer Mannheim Gmbh	Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
FR2649321A1 (fr) *	1989-07-07	1991-01-11	Inst Nat Sante Rech Med	Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
HUT69956A (en) *	1990-08-14	1995-09-28	Isis Pharmaceuticals Inc	Methode for inhibition of influenza virus by antiseuse oligonucleotides
US5994056A (en)	1991-05-02	1999-11-30	Roche Molecular Systems, Inc.	Homogeneous methods for nucleic acid amplification and detection
FR2687679B1 (fr) *	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
FR2686882B1 (fr) *	1992-02-05	1994-05-06	Centre Nat Rech Scient	Oligothionucleotides.
US6403302B1 (en)	1992-09-17	2002-06-11	California Institute Of Technology	Methods and compositions for triple helix formation
CA2114355A1 (en) *	1993-01-29	1994-07-30	Hidehiko Furukawa	Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
WO1999064434A1 (en) *	1998-06-11	1999-12-16	Isis Pharmaceuticals, Inc.	Synthetic methods and intermediates for triester oligonucleotides
US8241251B2 (en)	2004-08-25	2012-08-14	Tyco Healthcare Group Lp	Gel seal for a surgical trocar apparatus
US8357123B2 (en)	2007-09-17	2013-01-22	Covidien Lp	Surgical portal with gel and fabric seal assembly
AU2010203474B2 (en) *	2009-01-08	2015-11-19	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US8206358B2 (en)	2009-05-06	2012-06-26	Tyco Healthcare Group Lp	Ring and seal for trocar
US10874426B2 (en)	2017-02-10	2020-12-29	Covidien Lp	Seal assembly with integral filter and evacuation port
US11357542B2 (en)	2019-06-21	2022-06-14	Covidien Lp	Valve assembly and retainer for surgical access assembly

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2540122B1 (fr) *	1983-01-27	1985-11-29	Centre Nat Rech Scient	Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
JPS59213388A (ja) *	1983-05-20	1984-12-03	Akira Kaji	癌細胞増殖阻害方法
JPS60193922A (ja) *	1984-03-16	1985-10-02	Akira Kaji	抗ウイルス剤

1984
- 1984-07-25 FR FR8411795A patent/FR2568254B1/fr not_active Expired
1985
- 1985-07-22 EP EP85401506A patent/EP0169787B1/de not_active Expired
- 1985-07-22 DE DE8585401506T patent/DE3572825D1/de not_active Expired
- 1985-07-22 AT AT85401506T patent/ATE46170T1/de not_active IP Right Cessation
- 1985-07-24 CA CA000487402A patent/CA1321363C/en not_active Expired - Fee Related
- 1985-07-25 JP JP60165654A patent/JP2521426B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0169787A1 (de)	1986-01-29
EP0169787B1 (de)	1989-09-06
JPS6144820A (ja)	1986-03-04
FR2568254B1 (fr)	1988-04-29
FR2568254A1 (fr)	1986-01-31
JP2521426B2 (ja)	1996-08-07
CA1321363C (en)	1993-08-17
DE3572825D1 (en)	1989-10-12

Legal Events

Date	Code	Title	Description
1990-04-15	UEP	Publication of translation of european patent specification
1998-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE46170T1 (de)	1989-09-15	Verwendung von an ein interkalatines produkt gebundenen oligonukleotiden fuer pharmazeutische zusammensetzungen.
Baltimore et al.	1971	Primer requirement and template specificity of the DNA polymerase of RNA tumor viruses
BR9801878A (pt)	2000-09-19	Iniciadores de amplificação de ácido nucleìco modificado
DK0549615T3 (da)	2006-07-03	Sukkermodificerede oligonukleotider der påviser og modulerer genekspression
DE69636080D1 (de)	2006-06-01	Eine in Kaskaden verlaufende Vervielfältigungsreaktion von Nukleinsäuren
ATE207543T1 (de)	2001-11-15	Isotherme amplifikation von nukleinsäuren durch strangverdrängung
FI893526A0 (fi)	1989-07-21	Material och metod foer oekning av nukleinsyrahybridisering.
DE69431485D1 (de)	2002-11-07	Doppelsträngige peptidenukleinsäuren
DE69433626D1 (de)	2004-04-22	N-2 substituierte purine
ZA928839B (en)	1993-05-13	Rapid assays for amplification products.
DE3280400D1 (de)	1992-06-04	Oligonukleotides heilmittel und dessen herstellungsverfahren.
ATE58143T1 (de)	1990-11-15	Verbindungen, enthaltend eine oligonukleotide sequenz, gebunden an eine interkalierungsverbindung und an eine aktivierbare chemische verbindung, ihre synthese und verwendungen als artifizielle sequenzspezifische nuklease.
DK0919565T4 (da)	2009-01-12	Mærkede oligonukleotider
EP0285950A3 (de)	1990-11-07	Konjugate zur Wirkstoffabgabe
ATE87932T1 (de)	1993-04-15	Alpha-oligonukleotide.
EP1171634A4 (de)	2002-07-31	Amplifikation und sequenzierung von primer-paaren und deren verwendung
DE69815370D1 (de)	2003-07-10	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
LTIP1519A (en)	1995-06-26	Solution, set, process for elongation of the oligonucleotidic primer, process of dna amplification
IT7949883A0 (it)	1979-07-27	Ne detto prodotto procedimento per la sintesi enzimatica di un rna a doppio filamento prodotto ottenuto e composizione induttrice di interferone che contie
WO1994012518A3 (de)	1994-07-21	Reagenz zur kupplung veschiedener substanzen an nukleinsäuren sowie verfahren zu dessen herstellung
AU3964189A (en)	1990-01-05	Complete nucleotidic sequence of the complementary dna of the genomic rna of the potyvirus, genes coding for the potyvirus capside protein and application of said genes to the creation of potyvirus-resistant transgenic plants
SE8802479D0 (sv)	1988-07-01	Nucleic acid derivatives
Yoshida et al.	1982	Terminal Deoxynucleotidyl Transferase Help DNA Polymerase α Bypass Thymine Dimer
WO1993013204A3 (de)	1993-08-05	Mittel zur stimulierung der teilungsaktivität tierischer zellen
AU2782989A (en)	1989-07-05	Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes